Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechCHIX:DIMP 82 EV-to-EBITDA is 21.79 as of Jul. 29, 2026, which is 31% below its 10-year median of 31.59. GuruFocus rates CHIX:DIMP with a GF Score™ of 82/100 and a GF Value™ of €222.55 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 70.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sartorius Stedim Biotech's enterprise value is €18,748 Mil.
Sartorius Stedim Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €860 Mil. Therefore, Sartorius Stedim Biotech's EV-to-EBITDA for today is 21.79.
The historical rank and industry rank for Sartorius Stedim Biotech's EV-to-EBITDA or its related term are showing as below:
CHIX:DIMp'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 19.4 Med: 31.59 Max: 66.45
Current: 21.79
During the past 13 years, the highest EV-to-EBITDA of Sartorius Stedim Biotech was 66.45. The lowest was 19.40. And the median was 31.59.
CHIX:DIMp's EV-to-EBITDA is ranked worse than 70.12% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.25
vs CHIX:DIMp: 21.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sartorius Stedim Biotech's PE Ratio (TTM) for today is calculated as:
Sartorius Stedim Biotech's share price for today is €187.40.
Sartorius Stedim Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's EV-to-EBITDA falls into.
Sartorius Stedim Biotech's current Enterprise Value is €18,748 Mil.
Sartorius Stedim Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €860 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a EV-to-EBITDA of 21.79 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sartorius Stedim Biotech. This is 31% below median its historical median of 31.59. Over the past decade, Sartorius Stedim Biotech's EV-to-EBITDA has ranged from 19.40 to 66.45. According to the industry distribution chart, Sartorius Stedim Biotech ranks #359 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 70.1%.
Is Sartorius Stedim Biotech's EV-to-EBITDA too high?
Sartorius Stedim Biotech's current EV-to-EBITDA of 21.79 is 31% below median its 10-year median of 31.59. Over the past 10 years, this metric has ranged from a low of 19.40 to a high of 66.45. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.25. Sartorius Stedim Biotech's value of 21.79 is 52.9% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #359 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #359 out of 512 companies for EV-to-EBITDA. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median EV-to-EBITDA is 14.25. Sartorius Stedim Biotech's value of 21.79 is 52.9% above this benchmark. Historically, Sartorius Stedim Biotech's own EV-to-EBITDA has ranged from 19.40 to 66.45 over the past decade. While the company's 10-year median is 31.59 vs. the industry median of 14.25, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.25, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current EV-to-EBITDA of 21.79 is 52.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sartorius Stedim Biotech. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current EV-to-EBITDA is 21.79, which is 31% below median its own 10-year median of 31.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €222.55, compared to a current price of €187.40 — trading 15.8% below its estimated fair value. The current EV-to-EBITDA is 21.79, which is 31% below median its 10-year median of 31.59 and 52.9% above the Medical Devices & Instruments industry median of 14.25. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current EV-to-EBITDA is 21.79 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €187.40 is trading 15.8% below its estimated GF Value™ of €222.55.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
EV-to-EBITDA: 21.79 (31% below median its 10-year median of 31.59)
GF Value™: €222.55 vs. price of €187.40 (15.8% below fair value)
Industry Position: 52.9% above the Medical Devices & Instruments median (#359 of 512)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for CHIX:DIMP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
